Figure 1.
Study design of the HR-MDS cohort in FUSION-AML-001. Randomization and treatment schedule for patients enrolled on the FUSION-AML-001 trial. IV, intravenous; Q4W, every 4 weeks; sc, subcutaneous; 3-monthly, once every 3 months.
Study design of the HR-MDS cohort in FUSION-AML-001. Randomization and treatment schedule for patients enrolled on the FUSION-AML-001 trial. IV, intravenous; Q4W, every 4 weeks; sc, subcutaneous; 3-monthly, once every 3 months.